Abstract: The present invention relates generally to proteasome inhibiting ?-lactam compounds useful for the treatment of cancer and neurodegenerative disorders. The invention also provides pharmaceutical compositions and extended release formulations of said compounds, and medical uses of said compounds and/or pharmaceutical compositions to treat cancer and neurodegenerative disorders.
Type:
Application
Filed:
December 22, 2017
Publication date:
July 9, 2020
Applicants:
Vita Api, Etat Français Représenté Par le Directeur Central du Service de Santé des Armées, Université D'Aix-Marseille, Centre National de la Recherche Scientifique
Inventors:
Philippe Yves-Rémy Simon, Henri Oreal, Gérard Audran, Marvin Schulz, Jean-Patrick Joly, Didier Siri, Anouk Siri
Abstract: The present invention relates to a class-G immunoglobulin against the anthrax toxin protective antigen (PA), or one of the fragments of same, comprising at least: a variable heavy-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 1, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 1, and comprising the amino acids Leucine in position 51 and Glycine in position 67, and a variable light-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 2, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 2, and comprising a Leucine amino acid in position 55. The invention also relates to the uses of such an immunoglobulin.
Type:
Grant
Filed:
January 16, 2015
Date of Patent:
August 28, 2018
Assignees:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, ETAT FRANCAIS REPRESENTE PAR LE DIRECTEUR CENTRAL DU SERVICE DE SANTE DES ARMEES
Inventors:
Christian Behrens, Philippe Klein, Denis Hoguet